Skip to main content

Table 1 Baseline characteristics of PAF and PsAF patients underwent circRNA microarray analysis

From: The potential regulatory role of hsa_circ_0004104 in the persistency of atrial fibrillation by promoting cardiac fibrosis via TGF-β pathway

  PsAF (n = 6) PAF (n = 6) p value
Age, years 59.33 ± 6.09 58.67 ± 4.89 0.838
Male, n (%) 3 (50.0) 3 (50.0) 1.000
BMI, kg/m2 27.25 ± 1.47 25.45 ± 2.33 0.140
Heart rate, bpm 95.50 ± 18.21 87.00 ± 18.22 0.438
CAD, n (%) 0 (0) 1 (16.7) 1.000
HTN, n (%) 5 (83.3) 4 (66.7) 1.000
DM, n (%) 2 (33.3) 1 (16.7) 1.000
Smoke, n (%) 2 (33.3) 0 (0) 0.455
AF duration, months 9.2 ± 2.7 7.8 ± 3.1 0.291
LAD, mm 38.83 ± 5.67 39.00 ± 3.90 0.954
LVEF, % 64.50 ± 4.46 68.67 ± 5.39 0.175
LVEDD, mm 46.00 ± 4.05 47.92 ± 3.01 0.374
HbA1c, % 6.18 ± 1.03 5.86 ± 0.46 0.507
LDL, mmol/L 2.80 ± 0.42 2.87 ± 1.58 0.922
Creatine, µmol/L 64.98 ± 20.70 63.02 ± 17.55 0.863
BNP, pg/ml 1336.17 ± 806.4 1211.02 ± 741.18 0.385
β-blockers, n (%) 4 (66.7) 3 (50.0) 1.000
  1. Data are number (%) and mean ± SD
  2. PsAF, persistent atrial fibrillation; PAF, paroxysmal atrial fibrillation; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; HTN, hypertension; DM, diabetes mellitus; AF, atrial fibrillation; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; HbA1c, glycosylated hemoglobin; LDL, low density lipoprotein